Effects of Atorvastatin and Niacin, Alone and in Combination, On Lowering Serum LDL-Cholesterol and Lipoprotein (a) in Hyperlipidemia Patients
|Jhuma KA1*, Giasuddin ASM2, Haq AMM3, Huque MM3 and Mahmood N4|
|1Department of Biochemistry, Medical College for Women & Hospital, Plot-4, Road-9, Sector-1, Uttara Model Town, Dhaka-1230, Bangladesh|
|2Department of Medical Laboratory Science, State College of Health Sciences & Adjunct Professor, State University of Bangladesh, Dhanmondi, Dhaka-1209, Bangladesh|
|3Department of Medicine, Medical College for Women & Hospital, Plot-4, Road-9, Sector-1, Uttara Model Town, Dhaka-1230, Bangladesh|
|4Department of Medicine, (Nephrology Unit), Medical College for Women & Hospital, Plot-4, Road-9, Sector-1, Uttara Model Town, Dhaka-1230, Bangladesh|
|Corresponding Author :||Khadija Akther Jhuma
Associate Professor of Biochemistry
Department of Biochemistry
Medical College for Women & Hospital
Plot-4, Road-9, Sector-1, Uttara Model Town, Dhaka-1230, Bangladesh
E-mail: [email protected]
|Received February 17, 2014; Accepted March 11, 2014; Published March 20, 2014|
|Citation: Jhuma KA, Giasuddin ASM, Haq AMM, Huque MM, Mahmood N (2014) Effects of Atorvastatin and Niacin, Alone and in Combination, On Lowering Serum LDL-Cholesterol and Lipoprotein (a) in Hyperlipidemia Patients. J Metabolic Synd 3:136. doi:10.4172/2167-0943.1000136|
|Copyright: © 2014 Jhuma KA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Background & objectives: Effects of statins on serum lipids in hyperlipidemia are not well defined. We compared the effects of atorvastatin and niacin, alone and combination, on lowering serum LDL-C and Lp (a) and increasing HDL-C in hyperlipidemia patients.
Patients and methods: A total of 150 adult patients (Group-A) with hyperlipidemia and 100 normal adults controls (Group-B) were included in the study. The fasting blood samples were taken and serum (I°) were stored frozen until analysed for TG, TC, LDL-C, HDL-C, and Lp (a). The 50 patients (Group A1) were prescribed Atorvastatin (10 mg once daily for 3 months), 50 patients (Group A2) were prescribed Niacin (50 mg twice daily for 3 months) and 50 patients (Group A3) were prescribed combination of the two drugs with same doses for 3 months. Blood samples were taken again at follow up and serum (II°) was stored frozen until analysed for lipids by biochemical methods.
Results: Lipid parameters (mg/dl), i.e. TG, TC, LDL-C, & Lp(a), were raised and HDL-C was reduced in patients (Group-A) compared to controls (Group-B); Atovastatin (10 mg/ day) and Niacin (50 mg/2day) significantly lowered TG,TC, LDL-C & Lp(a) and raised HDL-C in Group A1 and Group A2 respectively; Combination therapy (atorvastatin: 10 mg/day + Niacin : 50 mg*2/day) was much more effective in lowering TG, TC, LDL-C & LP(a) and raising HDL-C in Group A3.
Conclusions: The effects of combination therapy of the two drugs were much higher than their effects alone and therefore, can be adopted in hyperlipidemia patients.